ModeX Therapeutics Awarded Contract to Address Public Health Threat From Viral Diseases
By Denny Jacob
ModeX Therapeutics, a OPKO Health company, was awarded a contract hailing from the Biomedical Advanced Research and Development Authority to advance candidates designed to address a range of public health threats in viral infectious diseases.
The clinical-stage biopharmaceutical company said the awarded funding would enable research, development and clinical evaluation of multispecific antibodies based on its proprietary technology.
The contract includes an initial $59 million for the development and execution of a clinical trial for a multispecific antibody with broad neutralizing abilities against known variants of the coronavirus known as SARS-CoV-2. Additional funding of up to $109 million may be available upon hitting certain milestones.
The Biomedical Advanced Research and Development Authority is part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
September 28, 2023 16:55 ET (20:55 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying
-
The 10 Best Companies to Invest in Now